Tirzep Injection 12.5 mg/0.5 ml contains Tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist designed for adults with type 2 diabetes mellitus (T2DM). By simultaneously activating both GIP and GLP-1 pathways, Tirzepatide enhances insulin secretion in response to elevated blood glucose, suppresses glucagon release, slows gastric emptying, and reduces appetite.

This higher-dose formulation is typically used after titration from lower doses to optimize glycemic control while balancing tolerability, making it suitable for patients requiring advanced diabetes management.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Tirzep Injection is indicated for:

• Adults with type 2 diabetes mellitus needing improved glycemic control
• Adjunct therapy in patients not adequately controlled with diet and exercise alone
• Combination therapy with oral antihyperglycemic medications if required
• Patients aiming for weight management alongside glycemic control

Mechanism of Action

Tirzepatide works through dual receptor agonism:

• GIP receptor activation: Increases glucose-dependent insulin secretion and improves postprandial glucose control.
• GLP-1 receptor activation: Reduces glucagon release, slows gastric emptying, and suppresses appetite.

The combined effect results in better fasting and postprandial glucose control, reduction in HbA1c, and support for weight management.

Dosage and Administration

• Administered as a subcutaneous injection once weekly.
• Dose escalation: Start at 2.5 mg, increase to 5 mg, 7.5 mg, 10 mg, and then 12.5 mg under physician supervision.
• Inject into the abdomen, thigh, or upper arm; rotate injection sites to minimize local reactions.
• Do not mix with other injectable drugs.
• Adherence to the prescribed schedule is critical for consistent glycemic control.

Benefits

• Significant HbA1c reduction in type 2 diabetes
• Supports weight management as part of comprehensive diabetes care
• Convenient once-weekly dosing enhances compliance
• Improves fasting and postprandial glucose levels
• Dual GIP/GLP-1 action provides superior metabolic control compared to single-agent therapy

Side Effects

Common side effects:

• Nausea, vomiting, or diarrhea
• Constipation
• Injection site reactions (redness, swelling, itching)
• Decreased appetite
• Mild headache or fatigue

Serious but rare side effects:

• Hypoglycemia, particularly when used with insulin or sulfonylureas
• Pancreatitis (persistent severe abdominal pain)
• Allergic reactions, including anaphylaxis
• Thyroid C-cell tumors (rare; contraindicated in patients with personal or family history of medullary thyroid carcinoma)

Immediate medical attention is required for severe reactions or pancreatitis symptoms.

Precautions and Warnings

• Not indicated for type 1 diabetes or diabetic ketoacidosis.
• Monitor patients with a history of pancreatitis or severe gastrointestinal disorders.
• Pregnancy and breastfeeding use only under medical supervision.
• Regular blood glucose monitoring is essential, especially with combination therapy.
• Use cautiously in patients with severe renal or hepatic impairment.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

Tirzep Injection may interact with:

• Other antidiabetic medications (increased risk of hypoglycemia)
• Oral drugs with narrow therapeutic indices (due to delayed gastric emptying)
• Medications affecting gastrointestinal motility

Always inform your healthcare provider about all medications and supplements being taken.

Storage

• Store in a refrigerator at 2–8°C; do not freeze
• Protect from light and heat
• Keep out of reach of children
• Do not use after the expiration date
• Follow package instructions for usage period after opening.